Results 211 to 220 of about 321,890 (253)

Letter No. 242

2021
openaire   +1 more source

Analysis of binding site for the novel small‐molecule TLR4 signal transduction inhibitor TAK‐242 and its therapeutic effect on mouse sepsis model

British Journal of Pharmacology, 2009
Kaoru Hazeki, Shizuo Akira, Y Iizawa
exaly  

SB 242 084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system

Neuropharmacology, 1999
Vincenzo Di Matteo, Giuseppe Di Giovanni, Michele Di Mascio   +2 more
exaly  

Combined Detection of CEA, CA 19-9, CA 242 and CA 50 in the Diagnosis and Prognosis of Resectable Gastric Cancer

Asian Pacific Journal of Cancer Prevention, 2014
Jianchun Yu, Wei-Ming Kang, Zhi-Qiang Ma   +2 more
exaly  

TAK-242 attenuates acute cigarette smoke-induced pulmonary inflammation in mouse via the TLR4/NF-κB signaling pathway

Biochemical and Biophysical Research Communications, 2016
Dan Wang, Shuyun Xu, Yaowen Jiang
exaly  

TAK-242 (Resatorvid), a Small-Molecule Inhibitor of Toll-Like Receptor (TLR) 4 Signaling, Binds Selectively to TLR4 and Interferes with Interactions between TLR4 and Its Adaptor Molecules

Molecular Pharmacology, 2011
Tatsumi Matsumoto
exaly  

Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model

European Journal of Pharmacology, 2007
Jun Sato
exaly  

Pre-operative serum levels of CA 242 and CEA predict outcome in colorectal cancer

European Journal of Cancer, 1996
M Carpelan-Holmström, Johan Lundin, Heikki Jarvinen   +2 more
exaly  

Evaluation of CA 242 as a Tumor Marker in Gallbladder Cancer

Journal of Gastrointestinal Cancer, 2011
Surinder Singh Rana, Usha Dutta, Radhika Srinivasan   +2 more
exaly  

Uruguay 242

2003
openaire   +1 more source